GlassScriptPhysician profile
Raymond P Smith
NPI 1477526259
$10,169.02
in general payments reported to CMS, 2019-2025
61 companies · $2,569 in 2025
The $2,569 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,272 · 2020: $733 · 2021: $550 · 2022: $838 · 2023: $1,666 · 2024: $1,541 · 2025: $2,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,536 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,536.14 |
| Education | $239.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $958.77 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $894.16 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $816.49 | 2019-2025 | Lynparza, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $628.03 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Pfizer INC. | $558.86 | 2019-2025 | |
| Genentech USA, INC. | $490.63 | 2019-2025 | Phesgo, Tecentriq, Kadcyla |
| E.R. Squibb & Sons, L.L.C. | $448.70 | 2019-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $422.29 | 2019-2025 | Enhertu, Injectafer |
| Astellas Pharma US INC | $391.67 | 2019-2025 | Vyloy, Xospata, Xtandi |
| Incyte Corporation | $364.02 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Amgen INC. | $330.13 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Genzyme Corporation | $254.54 | 2019-2025 | |
| Exelixis INC. | $235.52 | 2019-2025 | Cabometyx |
| Celgene Corporation | $202.79 | 2019-2025 | Reblozyl, Opdualag |
| Gilead Sciences, INC. | $185.48 | 2021-2025 | Trodelvy |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.